Literature DB >> 8567122

Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.

M A Izquierdo1, R H Shoemaker, M J Flens, G L Scheffer, L Wu, T R Prather, R J Scheper.   

Abstract

In addition to P-glycoprotein (Pgp), 2 proteins related to multidrug resistance (MDR) have recently been described. The Multidrug-Resistance-associated protein (MRP) is one of the ATP-binding-cassette (ABC) transporters. The Lung-Resistance Protein (LRP) is the major component of human vaults, which are newly described cellular organelles and thought to mediate intracellular transport processes. Using immunocytochemical methods, we have examined the expression of MRP and LRP among panels of human cancer-cell lines not selected for drug resistance which have been previously characterized for expression of Pgp, and in vitro response to a variety of anti-cancer drugs. Expression of MRP and LRP was observed in 47/55 (87%) and 46/59 (78%) cell lines, respectively. Statistically significant correlations were observed between expression of each of these 3 proteins and in vitro sensitivity to at least one drug classically associated with MDR. LRP showed the greatest individual predictive value, which also applied to several non-classical MDR drugs. Co-expression of 2-3 MDR-related proteins was observed in 64% of the lines and was, in general, associated with high relative levels of drug resistance. Previously identified "classic" MDR lines as well as "pan-resistant" lines concurrently expressed all 3 MDR-related proteins. Some highly drug-resistant cell lines without detectable MDRI/Pgp were found to express relatively high levels of MRP and LRP. The high prevalence of MRP and LRP expression observed in this large set of cell lines, which have not been subjected to laboratory drug selection, suggests that MDR mechanisms associated with these proteins may be widespread in human malignancies. Moreover, the overlapping of these more recently recognized MDR phenotypes with Pgp-type MDR results in a complex phenotype, the understanding of which may be of importance in the development of new drugs and design of clinical treatment protocols, particularly those seeking to employ strategies to reverse the MDR phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8567122     DOI: 10.1002/(SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-H

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets.

Authors:  G Musumarra; D F Condorelli; A S Costa; M Fichera
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

2.  Expression of lung resistance protein in patients with gastric carcinoma and its clinical significance.

Authors:  Zhong-Min Liu; Nan-Hai Shou; Xi-Hong Jiang
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

3.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues.

Authors:  A B Schroeijers; G L Scheffer; M J Flens; G A Meijer; M A Izquierdo; P van der Valk; R J Scheper
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

5.  Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice.

Authors:  Bao-Jin Zhai; Ze-Yong Shao; Chun-Liang Zhao; Kai Hu; Feng Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

6.  Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.

Authors:  J-J Yeh; N-Y Hsu; W-H Hsu; C-H Tsai; C-C Lin; J-A Liang
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

7.  Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Authors:  Shizuko Sei; Jodie K Mussio; Quan-en Yang; Kunio Nagashima; Ralph E Parchment; Matthew C Coffey; Robert H Shoemaker; Joseph E Tomaszewski
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

8.  Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.

Authors:  Pedro C Lara; Marta Lloret; Bernardino Clavo; Rosa M Apolinario; Luis Alberto Henríquez-Hernández; Elisa Bordón; Fausto Fontes; Agustín Rey
Journal:  Radiat Oncol       Date:  2009-08-06       Impact factor: 3.481

9.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

Authors:  Mar Creixell; Nicholas A Peppas
Journal:  Nano Today       Date:  2012-08-01       Impact factor: 20.722

10.  14-3-3ε boosts bleomycin-induced DNA damage response by inhibiting the drug-resistant activity of MVP.

Authors:  Siwei Tang; Chen Bai; Pengyuan Yang; Xian Chen
Journal:  J Proteome Res       Date:  2013-05-09       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.